Sporadic medullary thyroid carcinoma with a pedunculated intraluminal internal jugular vein recurrence: A case report and literature review  by Patten, Darren K. et al.
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Medullary  thyroid  carcinoma  (MTC)  is  an  uncommon  usually  slowly  progressing  neuroendocrine  tumour
that  arises  from  calcitonin  (CT) producing  parafollicular  C  cells  of  the  thyroid  gland.  It accounts  for  approx-
imately  5%  of  all  thyroid  cancers.  The  majority  of  MTCs  are  sporadic  (75%)  whilst  25% are  part  of  the  MEN
2  hereditary  syndrome  (MEN  2A and  MEN  2B  and  familial  MTC).  Mutations  of  the  proto-oncogene,  RET
(Rearranged  during  Transfection),  found  on  chromosome  10q11,  are  present  in  more  than  95%  of  heredi-hyroid
edullary carcinoma
etastatic medullary carcinoma
nternal jugular vein thrombus
umour  thrombus
hyroid malignancy
tary  MTCs  and  about  25%  of sporadic  MTCs.  MTC  metastasizes  primarily  via  lymphatic  spread,  to  central,
and  lateral  nodal  neck  compartments  and the  anterior  and  superior  mediastinum.  Distant  haematoge-
nous  spread  targets  the  lungs,  liver,  bone  and  brain,  and  is  presumed  to  be secondary  to  a  lymphatic
pathway.  There  are  no previously  documented  reports  of  a focal  pedunculated  metastases  located  within
the  jugular  vein.  We  present  the  ﬁrst  reported  case  of  a metastatic  MTC  lesion  found in  the  right  internal
jugular  vein  in a man  with  recurrent  MTC.
gical  © 2011 Sur
. Introduction
Medullary thyroid carcinoma (MTC) is an uncommon usually
lowly progressing neuroendocrine tumour that arises from calci-
onin (CT) producing parafollicular C cells of the thyroid gland.1–4
t accounts for approximately 5% of all thyroid cancers.5,6 The
ajority of MTCs are sporadic (75%) whilst 25% are part of the
EN 2 hereditary syndrome (MEN 2A and MEN  2B and familial
TC).7,8 Mutations of the proto-oncogene, RET (Rearranged during
ransfection), found on chromosome 10q11, are present in more
han 95% of hereditary MTCs and about 25% of sporadic MTCs.9
TC  metastasizes primarily via lymphatic spread, to central, and
ateral nodal neck compartments and the anterior and superior
ediastinum. Distant haematogenous spread targets the lungs,
iver, bone and brain, and is presumed to be secondary to a lym-
hatic pathway. There are no previously documented reports of a
ocal pedunculated metastases located within the jugular vein. We
resent the ﬁrst reported case of a metastatic MTC  lesion found in
he right internal jugular vein in a man  with recurrent MTC.
.  CaseA  54 year old man  presented to his local hospital in February
008 with a right sided thyroid mass. An ultrasound scan and ﬁne
eedle aspiration cytology (FNAC) were inconclusive. In March
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2008 he underwent a diagnostic right thyroid lobectomy from
which he made a good recovery. Histological analysis of this
specimen revealed a 2 cm MTC. The patient was  referred to Ham-
mersmith Hospital for further care.
The post-operative calcitonin and carcinoembryonic antigen
(CEA) levels were 35 ng/L (normal range <11.8 ng/L) and 7 ug/L
(normal range 0–5 ug/L), respectively. An ultrasound scan (USS) of
the neck did not reveal lymphadenopathy. Following normal uri-
nary catecholamine and metanephrine estimation and a negative
genetic screen for MEN2 syndrome the patient proceeded to a com-
pletion thyroidectomy with bilateral prophylactic neck dissection
in April 2008. There was no evidence of medullary carcinoma in
the remnant left thyroid lobe and none of the 45 central or left lat-
eral cervical lymph nodes removed contained malignant deposits.
However 4 of the 43 lymph nodes removed from the right cen-
tral and right lateral neck were positive for medullary carcinoma
(1 lymph node from the right central compartment and 3 cervi-
cal nodes from levels 2–4). The patient made a good recovery with
a normal serum calcium on no supplements at 2 week follow up.
After an initial fall in the calcitonin and CEA levels (to 13.4 ng/L and
2 ug/L respectively) in the subsequent months the calcitonin lev-
els began to rise to pre-re-operative surgery levels suggesting low
grade persistent disease (Figs. 1 and 2). A magnetic resonance (MRI)
scan and USS of the neck were performed in May  2009 revealing
only cytologically proven small reactive lymph nodes.
Open access under CC BY-NC-ND license.A  (whole body) pentavalent dimercaptosuccinic acid (DMSA)
scan was  performed (July 2009) which showed no evidence of
disease. By January 2010, the calcitonin and CEA levels had
risen to136 ng/L and a ﬂuoro-deoxy-d-glucose – positron emission
NC-ND license. 
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Fig. 1. Graph showing serum calcitonin levels from March 2008 to March 2011.
Fig. 2. Graph showing serum CEA levels from March 2008 to March 2011.
Fig. 3. (A) Ultrasound image of the 10 mm pedicled spherical lesion within the RIJV. (B) Ultrasound image showing pedicled lesion obtaining blood supply from adjacent
tissues.
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Fig. 4. (A and B) Microscopic images of the FNAC (performed on the neck nodes) stained with May  Grunwald Giemsa (A) and Papanicolaou (B), showing tumour composed
of  cohesive islands of cells with neuroendocrine features including granular (‘salt and pepper’) chromatin (×20).
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increased to 437 ng/L and 13 ug/L, respectively in May  2011 in keep-
ing with as yet unidentiﬁed distant metastasis.Fig. 5. (A and B) Macroscopic images (A) showing internal aspect of the sacriﬁ
omography (FDG-PET) scan of the entire body, performed in
ebruary 2010, revealed no evidence of metabolically active dis-
ase. The patient remained asymptomatic but by October 2010, the
alcitonin and CEA levels had risen to 274 ng/L and 10 ug/L, respec-
ively. At this time examination of the neck revealed a fullness at
evel 2 on the right. An USS of the neck revealed a 10 mm well-
eﬁned pedunculated mass laying within the right internal jugular
ein (RIJV) and possessing an independent blood supply (Fig. 3A
nd B).
Reactive looking lymph nodes were also visualised on the right
ide of the neck at level 3. One of the nodes underwent FNAC which
evealed dispersed nests of intermediate sized epithelial-like cells
ith granular chromatin and occasional nucleolus with dense mod-
rately abundant cytoplasm (Fig. 4A and B). Immunocytochemistry
n the thinprep sample revealed expression of calcitonin and
uclear expression of TTF-1 in keeping with metastatic medullary
arcinoma.
In view of these ﬁndings the patient underwent a repeat uncom-
licated right selective neck dissection (levels 2–4) with sacriﬁce
f the right IJV in February 2011 (Fig. 5A and B and Fig. 6). He made
 good recovery and was discharged 3 days following surgery.
Histological analysis conﬁrmed a 10 mm × 10 mm × 10 mm
olypoid lesion, showing features consistent with metastatic
edullary carcinoma of the thyroid, and with a stalk measuring
.3 cm in length. The tumour reached the endothelial surface of the
ein (Fig. 7A and B). Resection margins of the vein were free of
umour. In addition, metastatic medullary carcinoma was  found in
ust 1 of the 19 dissected lymph nodes.ht IJV with a 10 mm polypoid lesion situated to the right. (B) Magniﬁed view.
The patient attended clinic in March 2011 and remains asymp-
tomatic, with normal haemoglobin, calcium, urea and creatinine
levels. However the calcitonin and CEA levels remain signiﬁ-
cantly raised at 274 ng/L and 11 ug/L, respectively and have furtherFig. 6. Right side of neck post excision of RIJV and lymph node dissection (levels
2–4) demonstrating right common carotid artery and its bifurcation and right vagus
nerve.
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Fig. 7. (A and B) H&E stained histological images showing the pedunculated metastatic deposit (lower left) attached to the vessel wall (A) ((×2) and a high power view (B)
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. Discussion
Patients with sporadic MTC  typically present with a solitary,
alpable thyroid nodule or cervical lymphadenopathy.10 Less com-
only the presentation is with local compressive or invasive
ymptoms such as hoarseness, dysphagia or diarrhoea secondary
o high levels of circulating calcitonin.7 Lymph node metastasis
s present in 50% of patients presenting with a palpable thyroid
ass/nodule.11 The central (level 6) followed by the lateral com-
artments (levels 2–5) are the most common sites of lymph node
etastases. Further spread can occur to the contralateral cervi-
al lymph nodes and then to the mediastinal (level 7) nodes.11,12
istant MTC  metastases usually occur via haematogenous spread
o the lungs, liver, bone and brain with the consequent potential
ymptoms of abdominal discomfort, bone pain or change in cogni-
ive state.11,12
A timely diagnosis of MTC  is achieved via a thorough history,
ncluding a comprehensive family history with direct questioning
egarding associated diseases in familial disease, and a complete
xamination of the neck. FNAC, ideally with immunohistochem-
cal staining for calcitonin aids diagnosis but may  not always be
iagnostic.7,8 In addition the routine or targeted measurements of
erum calcitonin may  be adopted to screen or conﬁrm a suspicion
f MTC  when suspected.7,8 Genetic analysis for RET mutations, and
creening for phaeochromocytoma with measurements of plasma
r urinary metanephrines and catecholamines as well as vocal cord
nalysis are mandatory.13 For patients with elevated calcitonin lev-
ls, USS for the assessment of lymphadenopathy is recommended
lone or with computer tomography (CT) or magnetic resonance
maging (MRI) of the chest and mediastinum.13
The mainstay of treatment of MTC  is surgical resection since
TC  do not capture and concentrate iodine and at present show
oor response to available adjuvant regimens in all but advanced
isease. For this reason a pre-operative diagnosis and optimal
rst time surgery represent key to good patient outcomes to the
oint that the ﬁrst operation in MTC  remains a key predictor of
utcome. The American Thyroid Association (ATA) and National
omprehensive Cancer Network (NCCN) have released guide-
ines on management of MTC  depending on size of the resected
umour.13,14 For unilateral tumours less than 1 cm a total thyroidec-
omy is recommended with the consideration of dissection of the
evel 6 lymph nodes. For MTC  tumours greater than or equal to
 cm and/or multifocal disease, total thyroidectomy with routine
ilateral central neck dissection is advocated. For ipsilateral or con-
ralateral cervical lymph nodes that are clinically or radiologicallyroendocrine differentiation) consistent with medullary carcinoma. Amyloid is also
apparent, ipsilateral or bilateral modiﬁed neck dissection, respec-
tively, are advocated.13
The patient reported above underwent a diagnostic right thyroid
lobectomy due to an inconclusive USS and FNAC. Despite subse-
quent radical surgery the disease remained poorly controlled. The
unusually sited and relatively large metastasis within the IJV was
eventually detected with neck USS but not detected with DMSA or
FDG PET-CT scans. Tumour thrombi in the IJV from FTC and PTC are
well documented but no reports of MTC  thrombi have been docu-
mented in a recent review of tumour thrombi.15 However it is clear
that the implications of such ﬁndings – a very high risk of distant
metastasis – remain true to MTC  as well as PTC.
The postoperative management and surveillance of MTC  is
based on regular serum calcitonin measurements and targeted
imaging.16 Serum CEA levels may  be normal in patients with pre-
clinical MTC  but may  be useful during follow-up because high
concentrations or rapidly increasing concentrations indicate dis-
ease progression or dedifferentiation.17 If a signiﬁcant rise in
calcitonin or CEA occurs following thyroidectomy, further imag-
ing investigations (USS neck, CT, MRI, FDG-PET or bone scan) are
recommended to look for locally recurrent or metastatic disease.16
For asymptomatic patients with negative imaging, surveillance 6-
monthly calcitonin and CEA is recommended.7,16
The strongest predictors of prognosis in patients with MTC
are stage of the disease and the extent of surgery.6,8,18,19 Patients
under the age of 65 (at time of diagnosis), who undergo surgery,
and who have a total thyroidectomy as opposed to a lobectomy,
have been shown to have longer survival. Improved outcome
is associated with female gender, well-diffferentiated histology,
small tumour size conﬁned to the capsule of the thyroid, lack of
lymph node involvement, and low post-thyroidectomy calcitonin
levels.6,18,20,21 The overall 5- and 10-year survival rates for MTC
have been reported to be between 80–97% and 75–88% respec-
tively of which the higher numbers having been obtained from
more recent reviews.19,21
4. Conclusion
This is the ﬁrst English language report of a pedunculated
tumour thrombus from MTC  located in the internal jugular
vein. The importance of appropriate ﬁrst time surgery in MTC
cannot be over-emphasised. The difﬁculty in the localisation
recurrent or persistent distant spread of MTC  remains a major
challenge.
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